Praxis (PRAX) jumps as FDA accepts tremor-drug NDA, AAN Phase 3 data in focus
Praxis Precision Medicines shares are rising after the FDA accepted its New Drug Application for ulixacaltamide HCl in adult essential tremor and set a Jan. 29, 2027 PDUFA target action date. Investor focus is also building into the American Academy of Neurology meeting in Chicago (April 18–22, 2026), where expanded Phase 3 Essential3 analyses are scheduled.
1) What’s moving PRAX today
Praxis Precision Medicines is moving higher as traders react to a key regulatory step: the FDA accepted the company’s NDA for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults. The FDA set a PDUFA target action date of January 29, 2027 and indicated it is not planning to hold an advisory committee meeting, reducing a common late-cycle uncertainty for biotech filings. (ir.praxismedicines.com)
2) Why the timing matters right now
The move is being reinforced by a near-term data spotlight at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago running April 18–22, 2026. Praxis has said it will present expanded analyses from its Phase 3 Essential3 program for ulixacaltamide, including a plenary talk slated for April 21 (Central Time) focused on maintenance of response and durability from a randomized withdrawal study. (globenewswire.com)
3) What investors watch next
After NDA acceptance, the next major swing factors typically become (1) any FDA information requests and labeling discussions, (2) commercial-readiness updates for a potential first neurology launch, and (3) incremental clinical/regulatory milestones across the pipeline. Separately, Praxis also has another late-stage regulatory clock running: relutrigine is under FDA priority review with a September 27, 2026 PDUFA target action date, giving investors multiple upcoming decision points. (investing.com)